Royal Bank Of Canada Issues Positive Forecast for Bausch Health Cos (NYSE:BHC) Stock Price

Posted by Geri Gentry on Oct 29th, 2026

Bausch Health Cos (NYSE:BHC – Get Free Report) had its price target lifted by analysts at Royal Bank Of Canada from $9.00 to $10.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price objective suggests a potential upside of 10.72% from the stock’s current price.

BHC has been the topic of a number of other reports. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Zacks Research upgraded shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Finally, Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $8.33.

Check Out Our Latest Stock Report on Bausch Health Cos

Bausch Health Cos Stock Up 30.5%

NYSE BHC traded up $2.11 during midday trading on Thursday, hitting $9.03. The company had a trading volume of 19,179,705 shares, compared to its average volume of 2,569,605. The firm has a fifty day simple moving average of $6.17 and a two-hundred day simple moving average of $5.71. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.95. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -3.03 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.52. The firm had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.72 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. As a group, equities analysts predict that Bausch Health Cos will post 4.35 earnings per share for the current year.

Insiders Place Their Bets

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the transaction, the insider owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors have recently modified their holdings of the stock. Pictet Asset Management Holding SA lifted its holdings in Bausch Health Cos by 4.1% during the first quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock worth $292,000 after acquiring an additional 2,114 shares in the last quarter. Roxbury Financial LLC bought a new stake in shares of Bausch Health Cos in the third quarter worth about $28,000. Tacita Capital Inc acquired a new stake in shares of Bausch Health Cos during the second quarter worth about $29,000. Lazard Asset Management LLC raised its position in shares of Bausch Health Cos by 15.5% during the first quarter. Lazard Asset Management LLC now owns 53,139 shares of the company’s stock worth $287,000 after purchasing an additional 7,114 shares during the period. Finally, Amundi raised its position in shares of Bausch Health Cos by 61.7% during the first quarter. Amundi now owns 23,983 shares of the company’s stock worth $130,000 after purchasing an additional 9,148 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

Positive Sentiment: Strong earnings and revenue beat: Third-quarter revenue reached $2.94 billion, up 10% year over year and above analyst estimates. Adjusted earnings per share were $1.77, compared with a $1.25 consensus estimate and $1.16 a year earlier. BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Positive Sentiment: Salix growth drove momentum: The Salix business, including Xifaxan, contributed to revenue growth, while consolidated adjusted EBITDA rose 32% to $1.305 billion. Bausch Health also reported its fourteenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth. Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue, adjusted EBITDA and adjusted operating cash-flow guidance, reinforcing expectations for continued operating improvement. The company generated $581 million in operating cash flow and $539 million in adjusted cash flow during the quarter. Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
Positive Sentiment: Debt reduction and buyback support sentiment: Bausch Health Americas plans to redeem approximately $643 million of 8.5% senior notes due 2027 using cash on hand, which could reduce interest costs and refinancing risk. The company also authorized a $50 million share-repurchase program, primarily to offset employee-equity dilution. Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Neutral Sentiment: Options activity was unusually elevated, with investors purchasing 6,018 call options—more than double typical call volume—suggesting increased bullish speculation but not guaranteeing further gains.
Negative Sentiment: The company continues to carry significant financial risk, including a history of negative net margin and highly negative return on equity. Redeeming debt with cash may improve leverage but reduces near-term liquidity.

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.